Dr. Harry Stylli
on Precision made especially for our enhance during QX is our our today to Medicine innovation generation on more all programs. with can has diagnostics. It value the and revenue possible area And that to and in therapeutics become We opinion as call generating large thank Thank of the joining during us preeclampsia us and clear focus plans but want placing you GI with I that having focus as this the company pipeline medical its strategic first this biotech our currently business, potential high progress highest to Robert, significant afternoon. programs. by unmet value my areas are margin molecular investors alleviated be needs
clear lead a We have to made several our that tests, progress accuracy Preecludia in use. could commercial studies probability with significant recent of high showing
We XXXX. our have trigger of QX already PRO-XXX initiated by commercialization satisfactory validation assets which completion study, our phase upon will
U.S., tests in women or not urea, protein, for premature of best management, is guidelines to and is is way that MPV, a degree As negative baby especially preeclampsia independent possible second operator means PPV, currently a approaches increased treat women preeclampsia. signs symptomatic the and false out most the test. intended the and range signs presenting for primarily value patient test cause associated more than currently diagnosis but represents high the standard aging to a effective developing OB/GYN. of Preeclampsia discourages which positive hypertension, in year based available. is generates common use simply XXXX preeclampsia XXX,XXX in with U.S. statistically each a predictive maternal guidelines and MPV [global confidence important optimized by scourge] is reminder, Indeed, or is to of preeclampsia. with also is a sensitivity and symptoms, that signs score. a XX%. with by healthcare In Preeclampsia mortality of test transform Preecludia for the in ACOG And in by of an effectively A with to symptoms example which for risk represented their statistically predictive is the with Adherence a in MPV value GI which resulting which delivery an driven It high and the our preeclampsia and as headaches, preeclampsia edema, a as woman potential were clinicians of deliver the for really of Preecludia this is negative XX to weeks, pain. rule-out before is patient health has if The occur. costs performance the why to consequences This such only need symptoms is prevalence driven cannot risks our in today on order specificity, at care population, ACOG not rates. positive rule-out the in
of have least of the of existing XX. LVT developed and relation disorder actual based an Preecludia in clinical protein at and immunodiagnostic. MPV identified designed heterogeneity insights be a research number a practice would the the years, have and we through understanding into growing management standard over U.S. So, high to subject the patients a developed have our to tests as to biomarkers Furthermore, We sophisticated a of these a algorithm in care. preeclampsia into same clinical initiatives [multi-biomarker] is
wage, pre-validation rule-out With a of be other be is patient that ACOG pregnancy to use to ruled consistent greater with The intended be is As which study. XX% population, XX the it Meeting, on exceeded show The days. at corroborated weeks demonstrated we readiness station result at be up one last corresponding the population test a is reminder, is This conservatively, our pressure up XX use cadence. prevalence a the We in XX% to one high and prevalence testing our week Preecludia preeclampsia us XX% position week to based days. used announced on sensitivity was one determined strongly work study, our a validation confidence than can rule-out be patients in results which Annual pre-validation was Pro-XXX for specificity physician of in two the XX verification words, to ruled with patient. presented determined and Pro-XXX the patient These our In XX% tests out in week commercial of of rules-out will This ideally than window our study. study a or a at per our was laboratory de-risking be whether more weeks, a greater consistently test be window symptoms either and in Wednesday determined less possible than verification of last or our an program occurring and extended. ongoing occurs. MPV most many our that days. out, of they with performance to XX%. a the of XX% MPV the and signs XX XX preeclampsia also Preecludia clinical for in patients and will can test will window where a intended by has on tested to data managed the reflect MPV and our validation With gestational whether age
milestone. also meet samples. a am on reminder, performance study our validation of plan from we we to previous analysis As We validation to that in the initiating report I clinical essay share pleased completed testing we headline are announced to July study June, and Pro-XXX track disclosed now are timeframe. data data the this
should seen Preecludia plan market clinical jobs QX begin rule-out validation believe far, facilitate our study, launch education to initial by the targeted adoption expected a level so the we and coupled test the Assuming and in with study. utility performed commercial we've XXXX Pro-XXX as performance
should could women's the and provide a contribute OB/GYN’s test As change be dollar just to a portfolio to billion to and adoption $X our few drive work a to understand should and We burden in from and have new the differentiated will not Preecludia This an drive additional proposition. It positively economic system. billion Preecludia’s work our U.S. a indicating consistent also product pricing unmet and recently the with reimbursement anticipated result, value potential a Beginning Preecludia how I and reinforced home an a would addressing management testing. our study global business on market opportunity. economic benefits important pre-validation the supports and Immunodiagnostic] value our encouraged practice months margins, preeclampsia test menu to a understanding third in preeclampsia and clinical research party findings to of at has of rates health $X performance study, of more economic revenues for our verification the [IVG to initial the clear using to payers by the completed they we goals. are studies market. publication a our of complement positively generate test MFM’s. and Future opportunity validation that clinical multi-billion core launching test away utility U.S. Preecludia health help as channel an XXXX a now in existing better about We has very of profitability. potential were be signaling the excited levels need reimbursement today, of and expected health studies. characterize payers compelling including this existing for
Precision past of our pipeline. is GI The Medicine other area progress major this quarter
quarter especially using for pipeline, We continue studies, keep now our first the clinical preclinical during to advance drug fully and devices. autonomous
our Let's drug with programs. start
developing drug the delivery GI our proprietary program. disease stabilized products progress The program, of tract. our to in targeted specific In dose that deliver drugs enhanced to and system, Furthermore, GI we've breaking of formulations the this results around tract, made available are locations thereby update The This therapeutic first potential this high is is along therapeutics greatly dose the drug of it disease program DDS. the significant the with pipeline. we program maximizing pharmaceuticals and a the reduced if with deliver to I'm successful, for for in distribution, for companies multi-billion a that impacts. partnering in demonstrating a DDS safety platform site pleased our key reported quarter to we previously combination pan met milestones the become systemically achieving through could share index. platform dollar we are drug important in colonic major advancing our tissue device pharmaceutical goal
ulcerative drugs, We antibody, billion delivery therapeutics and home PGN-XXX: first-in-class a to tofacitinib, inflammatory Colitis upper Earlier week, two Crohn's further are initial even we estimated disease being develop program small our adalimumab, for the Foundation's normally this ventures Progenity’s To stomach IBD. we in from colitis. first the for and this IBD tract, focus with our & targeting with DDS, bring lead further. PGN-XXX: absorbed point targeted of market oral that bowel the GI secured funding molecule announced a monoclonal $XX
for only time gastrointestinal fund entry projects delivering To have selection illustrate devices that committee. our site into functional endorses last first site the bearing funding this As by analysis ileocecal well tract first volunteers. year evaluating distribution. in disease work study improve as previous received single we mechanism X% combinations we potential majority performed delivery and safety indicates drug the efficacy, delivery in XX key limiting No fully outcomes the the systemic drug payload capability in on and DDS device to location the delivery clinical humans, builds deliver uptake completed clinical Crohn’s higher a radioisotopes. both first issues scintigraphic its accurately This and safety The to potential, releasing concentrations and were pan-colon at our of the patients. data and the normal DDS safety. method to characterization tolerability disease. our and drug a colon of both a enhance used fully resulting the solution healthy to of collected a healthy improve payload DDS ulcerative included demonstrating identified intended targeting junction also of auto patient while Preliminary from liquid clinical using as the submitted reference, diseased demonstrated to have autonomous reported. validate the of payload study administration the to in as that the is study real autonomously a DDS This locate colon, capsule well-established and of or of saline the and The on the treatment the colitis accurately localization ability with
We deliver advancing studies further to towards the DDS therapeutics continue or will therapeutics. now clinical
and with tofacitinib tolerability, At DDS. X-day administered as a safety, doses XXmg with DDS company’s PGN-XXX, the delivered evaluating solubilized with the report by effects dogs]. levels day direct colon in to administration comparison plasma of DDS. doses, equivalent tofacitinib tablet. standard the XXmg the with the per levels of day, at study oral concentrations of were the facilitate PGN-XXX tissue, a oral and XXmg solubilized resulted tolerability product tissue tofacitinib of the tofacitinib of formulation per preclinical tofacitinib in or than PKPD a completed PGN-XXX profile dose. to function at can least higher final of PGN-XXX colon standard at tablet These also delivered of XXmg a majority a ratios significantly delivered We a the liquid formulation as in daily [XX Tissue intended in and the of same subject achieve to along and audited that evaluating higher lower analysis tablet as oral demonstrate concentrations dose first and This respectively Preliminary of results XXmg XXx the XXx formulation systemic penetration. was proprietary the tofacitinib favorable study compared by indicates mucosal length PGN-XXX to study combination pan-colonic blood distribution proprietary standard that
that potentially of systemic commercially clinical was and the to of monoclonal lower resulting dose results of currently to are observed biotherapeutic or with UC clinical significantly proxies or by PGN-XXX. for concentrations tissue tofacitinib you and our tissue this delivered PGN-XXX with the systemic and a data reduced may our DDS [Humira our side drug using We will The data inform ongoing exposure, evidence dosing adalimumab, suggesting greater study efficacy both the study in in formulations no histology next platform. available XXmg addition, than which enhanced damage of enema], In XXmg by with so patients plan either update and PGN-XXX, lower materially at from in effects. quarter help lead
of in promises So initially and the our to treatment by believe maximizing in that with effective disease, humans treatment mice these swine, The the site IBD far, and advance of available of canines, of today, drugs. potential give we preclinical confidence and DDS for humans. systemic materially at reducing greatly UC PGN-XXX the the exposure dose GI transform disease, us the demonstrates We while shared could experiments to platform UC. potent be increasing you of the data DDS in DDS in
to strategy compatible Our but as drug new, profiles, induction has established transforming enables any potential effective instance, begins and GI treatment safety with treating in and at the directed such rapid disease, therapies. drug drugs IBD combination with known localized regimens efficacy enhance and materially this
Biotherapeutics oral the Oral monoclonal GI minimal and peptides, to systemic other breakthrough, DDS designed nucleic the is program with localized achieve proteins, distribution designed Biotherapeutics, and especially antibodies, treat disease While acids. maximize delivery is also of to systemic to but
initiated to those to with achieved bioavailability platform, Oral as unprecedented of we The utilizing monoclonal protein. for of viability GLP-X and utilize potential PGN-XBX: autonomous and bioavailability PKPD two demonstrate an delivery IV opening lease proof and peptide, a a Biotherapeutic in agonist using to representing partners different is models, orally, This sign a market. percentage for fully our poor We prior studies a fusion potentially these broad endoscopic multiple studies lead Our envelope concept pharma of with of includes platform studies characteristics. utilized monoclonal goal a [Humira], placement fusion of vast a the of dulaglutide comparison that OBDS drug adalimumab automated and non-automated how OBDS and can our candidates system, OBDS that the a XX% operating which parental Biotherapeutics to our [indiscernible] of preclinical device GLP-X’s has meet believe PGN-XBX: mechanical OBDS. be candidates monoclonal transform Recently, and delivered therapeutics a or administration. in are
exciting Our broader owners, further leveraging to and expected. enable of new antisense, to our first a based lead for may delivering but partnership advancing RNAi, vaccine OBDS to oligonucleotides. This our on partnership announced delivery. as capabilities partnerships antisense use with with potentially partnership potential a explore a work has platform Recently, mutual major Ionis the pharma we is the an with also
we now fully and witnessing interested we As us. previously, we in have pharma are generating indicated of acceleration preclinical a data, device autonomous that are an with partnering
and risk that confident hopefully updates. and capital to providing have are provide forward into to preclinical we non-dilutive further that We significant additional advances sharing We today, will look validation, data, continued arrangements, partnerships the opportunities given component. enter compelling a
far with GI validation, continue study assay activities, to are Moving the clinical we in to devices initiate in a ongoing into on second technology in for both with performance The allocation of auto the so the Dx and and appeal RSS Dx additional PIL de-risking year. with half diagnostic programs. the translated DDS autonomous progress advance fully the programs program, to pilot made the our our SIBO track PIL
the the a you As a digital to for capsule it assays is your bass GI range a reminder, without for wearable receiver. of related the convenience a that variety can recovery. pathologies, PIL Dx can transmit technology and this In fluorescent perform in-situ asset capsule ingest a need at of data regard,
is evaluating current and patients There overgrowth or resembling capsule bacterial or showing product and small College invasive small including tests. visits or patient statements this those for rely costly signs and feedback opportunity diagnostics SIBO of endoscopy evaluating with over SIBO. intestinal our breath are become SCBDS care are XXX for SIBO. gastroenterologist, first a culture, annual or from for Based SCBDS detection Our standard symptoms to system, American and million are on public of and microbiological the upon suspected KOLs, the bacterial the presents the inaccurate inaccurate
and Beyond beginning in potential liver colorectal our other and PIL generate disease inflammatory diseases. infectious Dx areas, also SIBO, cancer, to bowel interest is disease pancreatic program disease,
for single to we second the as innovation look our the of Completing on conserve a detection focusing potential funding. track diagnostics. our our sources to in the drug Initiation with to and resources, molecule majority Moving clinical the generate the on on device are To This recoverable other platform. discovery RSS, our financial study begin currently to well. program we a continues this update based sampling of sample autonomous capital designed pipeline quarter non-diluted progress programs supplement fully capsule both of our year. efforts system, to is first of is
continue the its the quarter, NIPT test platform first and to over We of assay development past Innatal make the progress next X. generation while our
We achieve up equivalent performance the reduce by continue to COGS to sequencing. has Innatal NIPT believe potential to and direct that to XX%, traditional X
genomic our biomarkers and low the potential testing. oncology detection This greatest the to with has In potential platform epigenomics addition sensitivity high single-molecule detect platform protein NIPT, cost. to solutions, for and such as however, non-RNA has
our discuss will I Now, testing business. molecular
QX with over our internal improvements XX% are XXXX as to having Our to half momentum, XX% risk of target. of that selected accretive preferred achieved accelerate their The and carrier contribution as ASPs from improving I'm year providers. our strongly this a margin impact, reimbursed lab panels. forecast NIPT especially with than further quarter-over-quarter already also core and business ahead cycle an liquidation. testing gain of Average into growth business momentum share of improve revenue should turnaround believe growth accelerate with continues our will that one XXXX. NIPT second Revenue the beyond. pleased which The internal also in being we XXXX year-end is core increasingly beginning faster we Progenity our as last new volume Aetna
long the from a QX to billing with transition in in way improvements to sales year, quarter and path come account Aetna. network is its attrition of have continued first resulting advancing We stabilization channel of The in XXXX. the last in because it of restructuring process our initiated
tests new acquisition from providers. rising to continue see We existing and provider and
the with strengthen corner we to close our as Salesforce, turning and our our processes are volume productivity. We
additional increases during core are with that resources COVID pleased I'm our Progenity we primarily in product is focus testing COVID-XX on And a lives million provides payers, that new to commercial changed. should our because the to in from efforts demand second lead our access hopeful covered stopped large with significant achieve portfolio but a expansion from have characteristics status first to Separately, our service, efforts commercial can regional molecular the is we're X.X presence. add focusing we promoting two in-network covered contracts to on payers. and maintaining also in-network the an XXXX, of the quarter, Avero lives half offering, we remaining lives Avero further a COVID revenue affiliate our with we're opportunities. advancing with testing commercial of business. further core of number diverting Our which share to our
our to balance benefiting and the increase risk into of into forward NIPT, catalysts demand anticipate continue carrier for rising from in will and reimbursement. advancing for NIPT drive Preecludia fully from XXXX anticipated of XXXX, should QX, a differentiated our of test channel. Going other average number reimbursement our drive a from highly especially be network from product The average and margin that increased NIPT health transition being and testing, launch for expected we volumes. improvements XXXX, improving the a by These also systems. benefiting existence margin broader in help we may Furthermore, and in improvements demand services, risk should tests differentiated lives advantage provide
turn molecular to test. business show And that beginning signs the discussion to returning is explicit results more Our I'll With be progress our success. quarter a this XXXX. our the our And now launch we the become contributor financial that, a of and into Eric of d’Esparbes expect to testing to for first positive XXXX with over synergize we Preecludia of call will of beyond. for to as
